New to Generics Bulletin?
Request a free trial today!
Register for our free email digests:
Register for our free email digests:
Samsung Bioepis Co., Ltd.
http://www.samsungbioepis.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Samsung Bioepis Co., Ltd.
Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Samsung Bioepis First To File EU Lucentis Rival
Samsung Bioepis has beaten its rivals to become the first firm to announce successful filing of a ranibizumab biosimilar rival to Lucentis in the EU.
Samsung Bioepis Receives EU Bevacizumab Approval
With the European Commission’s approval of Aybintio (bevacizumab), Samsung Bioepis now has five approved biosimilars for Europe.
Capacity, Expertise Drive Korea's Emergence As COVID-19-Related Manufacturing Base
A series of major COVID-19-related manufacturing deals reached by South Korean firms indicate the country could emerge as a major base for the production of drugs and vaccines.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Samsung Biologics
- Samsung Bioepis JV
- Samsung Bioepis BR Pharmaceutical LTDA
- MORE